Results 221 to 230 of about 174,356 (352)
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial. [PDF]
Nat CommunRose AAN, Maxwell J, Rousselle E, Mukonoweshuro CL, Elkholi IE, Riaud M, Biondini M, Cianfarano E, Soria-Bretones I, Tobin C, McGuire M, Law RWY, Elia AJ, Wang BX, King I, Zhang T, Pugh TJ, Kamil ZS, Butler M, Shepherd FA, Leighl NB, Razak AA, Hansen A, Saibil SD, Bedard PL, Siegel PM, Siu LL, Cescon DW, Spreafico A. +28 moreeuropepmc +1 more sourceSupplemental Figure 2 from Clinical Utility of a Blood-Based BRAF<sup>V600E</sup> Mutation Assay in Melanoma
, 2023 David J. Panka, Elizabeth I. Buchbinder, Anita Giobbie‐Hurder, Aislyn Schalck, Laleh Montaser‐Kouhsari, Alireza Sepehr, Donald P. Lawrence, David F. McDermott, Rachel Cohen, Alexander Carlson, Jennifer A. Wargo, Ryan Merritt, Virginia Seery, F. Stephen Hodi, Anasuya Gunturi, Dennie Fredrick, Michael B. Atkins, A. John Iafrate, Keith T. Flaherty, James W. Mier, Ryan J. Sullivan +20 moreopenalex +1 more sourceSupplementary Figures 1 - 4 from BRAF Inhibition Alleviates Immune Suppression in Murine Autochthonous Melanoma
, 2023 Shannon M. Steinberg, Peisheng Zhang, Brian T. Malik, Andrea Boni, Tamer B. Shabaneh, Katelyn T. Byrne, David W. Mullins, Constance Brinckerhoff, Marc S. Ernstoff, Marcus Bosenberg, Mary Jo Turk +10 moreopenalex +1 more sourcePSMD12 Overexpression Promotes Lung Adenocarcinoma Progression via Ubiquitin–Proteasome Pathway Dysregulation
Cancer Science, EarlyView.PSMD12, located on the frequently amplified 17q region in LUAD, is upregulated in tumors and associated with poor prognosis and advanced stage. Functional studies revealed that PSMD12 promotes cell proliferation and G2/M transition by inhibiting CDK1 ubiquitination and stabilizing CDK1.Yuya Ono, Hajime Otsu, Takaaki Masuda, Keisuke Kosai, Shohei Shibuta, Kosuke Hirose, Takashi Ofuchi, Yuki Ando, Koto Kawata, Yasuo Tsuda, Yusuke Yonemura, Taro Tobo, Tomoyoshi Takenaka, Tomoharu Yoshizumi, Koshi Mimori +14 morewiley +1 more sourceHigh BRAF variant allele frequency predicts poor outcomes in metastatic melanoma patients treated with BRAF/MEK inhibitors. [PDF]
J Transl MedGuida M, Apollonio B, Romano L, Spagnolo F, Quaglino P, Depenni R, Pinto R, Squicciarini T, Fucci L, Di Tullio P, Scaini MC, Maccallini MT, Indini A, Troiani T, Natalicchio I, Brugnara S, Lombardo M, Pellegrini C, Queirolo P, Perrone F, Minisini A, Tucci M, Conca R, Costabile S, Macrì M, Tanda E, Croce E, Senetta R, Fava P, Pugliese G, Pellegrini S, Melucci E, Vecchio MD, Caraglia F, Girlando S, De Summa S, Strippoli S, Italian Melanoma Intergroup (IMI). +37 moreeuropepmc +1 more sourcePrecision Oncology for Pediatric Solid Tumors Using In‐Hospital Pediatric/AYA Malignancy‐Specific Panel Sequencing
Cancer Science, EarlyView.Our findings indicate that a pediatric/AYA‐specific targeted panel deployed in a hospital can deliver rapid, clinically actionable molecular insights with high diagnostic and prognostic yield. This complements larger sequencing platforms by offering speed, focused content, and easier interpretation.Masato Kojima, Sho Kurihara, Isamu Saeki, Ryo Touge, Keigo Nakashima, Shuhei Karakawa, Fumiyuki Yamasaki, Satoshi Okada, Eiso Hiyama +8 morewiley +1 more source
